Adjuvant Immunotherapy After Melanoma Surgery — Who Needs It, and For How Long

Most people who have had a melanoma removed do not need it. Adjuvant immunotherapy is discussed only when the surgical pathology report shows a high risk of the melanoma returning. In practice that usually means melanoma that had reached the lymph nodes, and sometimes a deep or ulcerated primary that had not. Stage decides this conversation, not preference.

“Adjuvant” means additional. It is treatment given after surgery has already removed everything that could be seen or felt, to lower the chance of the disease coming back from cells too small to detect. Nothing is visible on a scan at that point. That single fact shapes everything else on this page.

Three things in the pathology report do most of the work. How deep the melanoma had grown into the skin, measured in millimetres. Whether the surface was ulcerated. And whether melanoma cells were found in a lymph node, which is why a sentinel node biopsy is often done at the time of surgery. Those three findings together produce the stage, and the stage is what opens or closes the adjuvant discussion.

Your medical history is the second gate. Active autoimmune disease, a previous organ transplant, or ongoing high-dose steroids can make immunotherapy unsuitable or higher-risk. Checkpoint inhibitor treatment works by loosening restraints on the immune system rather than by attacking cancer cells directly, so an immune system that is already over-active is a genuine clinical problem, not a formality.

Subtype is the third, and it matters more in India than most pages admit. Melanoma here often starts on the sole of the foot, on the palm, under a nail, or on an internal lining. Those subtypes are under-represented in the trials that established adjuvant treatment, which is set out in Acral and Mucosal Melanoma in India: Does Immunotherapy Work?. Adjuvant treatment is still discussed for them. The expected benefit should just be described honestly rather than borrowed from a different disease.

Nothing on this page decides eligibility. That rests on the surgical pathology report, the stage, your medical history and overall fitness, read together by a medical oncologist.

For a defined period, not indefinitely. Current NCCN and ESMO guidance, as of August 2026, sets adjuvant treatment after melanoma surgery at about one year. Infusions are given as day care on a fixed schedule, commonly every three to four weeks or every six weeks on an extended-interval schedule, and then the course stops on a planned date.

That fixed end point is one of the more reassuring things about adjuvant treatment, and it is worth saying early. This is not treatment that continues for as long as it appears to be working, because there is nothing visible to watch. It is a course with a start and a finish, planned before the first infusion.

Each visit follows the same shape. Blood tests are checked before the cycle is released. The infusion itself takes under an hour for most people, with a period of observation afterwards. You go home the same day. An overnight stay is not part of a routine cycle.

A lower chance that the melanoma comes back. That is the whole aim. Surgery has already removed everything visible, so nothing shrinks and no scan will show the treatment working. Guideline bodies including NCCN and ESMO report fewer recurrences in treated groups than in observed groups. That is a reduction in risk, not a removal of it.

This is where careful language matters, and where a lot of what you will read online goes wrong. Oncologists talk about lowering the risk of recurrence. They avoid stronger words deliberately, even in melanoma, where long remissions are genuinely well documented. The reason is simple: a year of treatment changes the odds for a group of patients, and no one can tell you in advance which side of those odds an individual will land on.

Two uncomfortable truths sit inside that. Some people complete the full year and the melanoma returns anyway. And some people who complete the full year would never have relapsed even without it — they were treated, and had side effects, for a benefit they did not personally need. Both are true at the same time, and both are part of the conversation you are entitled to have.

That is also why doing nothing is a real option here rather than a polite fiction. Close surveillance instead of adjuvant treatment is offered in current guidance for several risk groups. It means planned clinic reviews, skin and lymph node examination, and imaging at set intervals, so that a recurrence is found early and treated then.

Nobody should make this decision on a website. What follows is the framework a medical oncologist will use with you, so that you walk into that conversation knowing what is being weighed.

• How high is the risk of return, actually? Ask for it in plain terms — low, moderate or high — based on depth, ulceration and node status. The higher the risk, the more a year of treatment is worth considering.
• What is the side-effect exposure over a full year? Most are manageable. A minority are not, and a few — thyroid and other hormone changes in particular — can be permanent. This is the price side of the trade, and it should be quantified in conversation, not glossed over.
• What does the surveillance path look like if I decline? Ask for the actual schedule of visits and scans. A vague “we will keep an eye on it” is not a plan; a written follow-up schedule is.
• Does my subtype match the evidence? If the melanoma is acral or mucosal, ask directly how well the trial evidence transfers. An honest answer here is a good sign, not a worrying one.
• What is the plan if it comes back either way? Knowing there is a defined next step, and what it is, usually makes the first decision easier to take rather than harder.

Mostly because melanoma is uncommon here. Fewer teams see enough of it for adjuvant treatment to be a routine reflex after surgery. Add a subtype mix that fits the trial evidence less well, a year-long course that costs money and time, and a treatment with nothing visible to show for it, and the conversation often simply does not happen.

Each of those is worth separating, because only some are good reasons. Volume is a real one: a surgeon who removes a handful of melanomas a year is not thinking in the same grooves as one who sees them weekly. Referral onward to a medical oncologist after clean melanoma surgery is not yet automatic in many Indian centres, and if that referral does not happen, the option is never raised.

The subtype question is a genuine scientific caveat rather than an excuse. Much of the adjuvant evidence was built in populations with sun-exposure-driven melanoma. Indian patients more often have acral or mucosal melanoma, where the evidence base is thinner. That argues for an honest conversation about expected benefit. It does not argue for silence.

Cost and duration matter too, and pretending otherwise helps nobody. A year of day-care infusions is a commitment of money, leave from work and travel. It is exactly the kind of thing that should be costed openly before you start, with insurance cover or scheme eligibility confirmed in advance rather than discovered halfway through. At CION, that conversation happens before the first cycle, not after it.

One clarification that avoids a common mix-up. Adjuvant treatment after surgery normally uses a single checkpoint inhibitor, not the two-drug combination used in advanced melanoma. The combination delivers more benefit in visible disease and considerably more immune-related toxicity, a trade-off explained in Dual Immunotherapy for Melanoma: Higher Benefit, Higher Risk. In the adjuvant setting, where many patients would have been fine without any treatment, that toxicity balance falls differently.

If melanoma surgery has already happened and nobody has raised what comes next, that is worth a second opinion rather than a wait-and-see. The pathology report is all a medical oncologist needs to answer the question.

Side effects come from the immune system acting on healthy tissue, so they can appear anywhere and at any time. Thyroid changes are among the most common and are usually found on blood tests rather than felt. Rash, itching, tiredness, joint aches and loose motions are frequent. Serious reactions are uncommon but need same-day contact, not home management.

Call the CION helpline on 1800 202 8726 the same day, or go to the nearest emergency department, for any of the following: loose motions that are increasing in number, blood or mucus in the stool, new breathlessness or a cough that will not settle, chest pain or palpitations, severe abdominal pain, yellowing of the eyes, or sudden confusion, collapse or extreme weakness. Do not treat these at home and do not wait for the next scheduled visit.

There is a specific reason to hold that line during an adjuvant year. You feel well. The melanoma has been removed, there is nothing to see on a scan, and it is very easy to write off a new symptom as unrelated to a treatment that is preventing something rather than fighting something. Immune-related reactions do not care that you feel well, and they are far easier to manage early than late.

Some effects last beyond the course. Thyroid changes in particular can be permanent, and some people take thyroid tablets for life afterwards. That is manageable and not a catastrophe, but it belongs in the decision, not as a surprise at month eight.

One change is more encouraging than it looks. Patches of skin losing their pigment, or hair turning white, can happen during melanoma immunotherapy. It is usually harmless, and what it appears to indicate is discussed in Vitiligo During Melanoma Immunotherapy: A Good Sign?. Report it, as you would any change, but it is not a reason for alarm.

Tell every doctor you see during the year, and for a long time afterwards, that you have had immunotherapy. That includes a dentist, a physician treating a fever, and any emergency department. It changes how new symptoms should be interpreted.

• If the melanoma started on a sole, a palm, a nail bed or an internal lining, the evidence transfers less well and you deserve to know why — Acral and Mucosal Melanoma in India: Does Immunotherapy Work? sets out what is and is not known.
• Adjuvant treatment normally uses one checkpoint inhibitor rather than two. Why the combination is reserved for visible disease is explained in Dual Immunotherapy for Melanoma: Higher Benefit, Higher Risk.
• Losing skin pigment during treatment surprises most patients — Vitiligo During Melanoma Immunotherapy: A Good Sign? explains what it is and what it appears to indicate.
• For how immunotherapy is delivered, monitored and paid for across our centres, see Immunotherapy at CION Cancer Clinics.

Still unsure how any of this applies after a specific melanoma surgery? Book a free consultation and a medical oncologist will go through the reports with you.